ADM Tronics Announces FDA 510(k) Application Filed for Angiodroid CO2 Injector for Angiography

Oct. 14, 2015 9:14 am |  More About ADM Tronics Unlimited


NORTHVALE, N.J., Oct. 14, 2015 /PRNewswire/ -- ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has announced that a Premarket Notification 510(k) application has been filed with the US Food and Drug Administration ("FDA") for Angiodroid The CO2 Injector for Angiography (the "Angiodroid Injector") by Angiodroid America, Inc., a subsidiary of Angiodroid, Srl, in affiliation with Triotech Ventures and ADMT, as previously announced.

Angiodroid, Srl, a privately owned Italian entity, has developed the first automatic injector for peripheral angiography using carbon dioxide gas (CO2), eliminating both the pathologies associated with iodine contrast medium that often is not tolerated by diabetic or nephropathy patients, and the risks and pain associated with the manual injection of CO2.

Angiodroid The CO2 Injector, approved for sale by the European Regulatory Authorities, has already been introduced in Europe, Middle East and Asian markets.  With the filing of the FDA 510(k), Angiodroid is completing its worldwide market expansion and presence.

Angiodroid America, Inc., founded last year, is a majority-owned subsidiary of Angiodroid, Srl of Bologna, Italy.  ADMT owns 20% of Angiodroid America, Inc. and provides it with engineering and regulatory services and will be the exclusive manufacturer of the device for the North American market.

The mission of Triotech is to support foreign medical technology companies with specialized services and finances to assist such companies to access the North American marketplace through a US-based subsidiary.  For each accepted project, Triotech selects a team of partners, companies and professionals with specific expertise for a particular project.  ADMT was selected to join the consortium to provide engineering, regulatory and manufacturing services for Triotech projects.

ADMT specializes in electronic medical device design, development and manufacturing for diagnostic and therapeutic medical technologies at its FDA-Registered Medical Device Manufacturing Facility. The Company is a one-stop source for complete design, engineering, regulatory and manufacturing services. ADMT has a number of proprietary medical devices. These proprietary devices, conceived, designed and produced in-house, include therapeutic and diagnostic medical technologies in fields as diverse as audiology, physical medicine, wound therapy, neurology and urology.

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products.  Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house.  ADMT has three Business Segments: Proprietary Electronic Medical Devices; Eco-Friendly, Safe, Water-Based Formulations; and, Design, Engineering, Regulatory and Manufacturing Services.  The Company's headquarters, laboratories, medical device and manufacturing operations are located in Northvale, NJ.  ADMT's multi-disciplinary team of engineers, researchers and technologists employ advanced technology infrastructure, such as 3-D solid prototyping, precision instrumentation and specialized software and peripherals for the research, development and commercialization of diversified technologies. Additional information is available at the Company's websites - admtronics.com and concepttoquantity.com.

Except for historical information contained herein, the matters set forth in this news release are "forward looking" statements (as defined in the Private Securities Litigation Reform Act of 1995).  Although ADMT believes the expectations reflected in such forward looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations.  Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/adm-tronics-announces-fda-510k-application-filed-for-angiodroid-co2-injector-for-angiography-300159502.html

SOURCE ADM Tronics Unlimited, Inc.

PR Newswire
October 14, 2015 - 9:14 AM EDT


comments powered by Disqus

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market